Literature DB >> 25402414

Development of echinocandin resistance in Candida krusei isolates following exposure to micafungin and caspofungin in a BM transplant unit.

E Tavernier1, M Desnos-Ollivier2, F Honeyman3, M Srour4, A Fayard3, J Cornillon4, K Augeul-Meunier4, D Guyotat1, H Raberin5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25402414     DOI： 10.1038/bmt.2014.230

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

Authors:  Michael A Pfaller; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Journal:  Int J Antimicrob Agents       Date:  2011-04-22       Impact factor: 5.283

2.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-01-11       Impact factor: 8.067

Review 4.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors:  M A Pfaller; D J Diekema; D Andes; M C Arendrup; S D Brown; S R Lockhart; M Motyl; D S Perlin
Journal:  Drug Resist Updat       Date:  2011-02-24       Impact factor: 18.500

5.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia.

Authors:  Dhara N Shah; Raymond Yau; Todd M Lasco; Jaye Weston; Miguel Salazar; Hannah R Palmer; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

7.  Strain typing and determination of population structure of Candida krusei by multilocus sequence typing.

Authors:  Mette D Jacobsen; Neil A R Gow; Martin C J Maiden; Duncan J Shaw; Frank C Odds
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

8.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

9.  Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Dorothée Raoux; Damien Hoinard; Françoise Dromer; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

Authors:  Jo-Anne H van Burik; Voravit Ratanatharathorn; Daniel E Stepan; Carole B Miller; Jeffrey H Lipton; David H Vesole; Nancy Bunin; Donna A Wall; John W Hiemenz; Yoichi Satoi; Jeanette M Lee; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-10-27       Impact factor: 9.079
  10 in total
  9 in total

Review 1.  Investigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?

Authors:  Alexandre Alanio; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Stéphane Bretagne
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2022-04-12       Impact factor: 5.938

3.  Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.

Authors:  Hazim O Khalifa; Vit Hubka; Akira Watanabe; Minoru Nagi; Yoshitsugu Miyazaki; Takashi Yaguchi; Katsuhiko Kamei
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

4.  In vitro antifungal activity of essential oils extracted from plants against fluconazole-susceptible and -resistant Candida albicans.

Authors:  F Katiraee; S Ahmadi Afshar; S F Rahimi Pirmahalleh; H Shokri
Journal:  Curr Med Mycol       Date:  2017-06

5.  A Chitin-binding Protein Purified from Moringa oleifera Seeds Presents Anticandidal Activity by Increasing Cell Membrane Permeability and Reactive Oxygen Species Production.

Authors:  João X S Neto; Mirella L Pereira; Jose T A Oliveira; Lady C B Rocha-Bezerra; Tiago D P Lopes; Helen P S Costa; Daniele O B Sousa; Bruno A M Rocha; Thalles B Grangeiro; José E C Freire; Ana Cristina O Monteiro-Moreira; Marina D P Lobo; Raimunda S N Brilhante; Ilka M Vasconcelos
Journal:  Front Microbiol       Date:  2017-06-06       Impact factor: 5.640

6.  Population genomics shows no distinction between pathogenic Candida krusei and environmental Pichia kudriavzevii: One species, four names.

Authors:  Alexander P Douglass; Benjamin Offei; Stephanie Braun-Galleani; Aisling Y Coughlan; Alexandre A R Martos; Raúl A Ortiz-Merino; Kevin P Byrne; Kenneth H Wolfe
Journal:  PLoS Pathog       Date:  2018-07-19       Impact factor: 6.823

7.  Promising antifungal activity of new oxadiazole against Candida krusei.

Authors:  Daniella Renata Faria; Karina Mayumi Sakita; Isis Regina Grenier Capoci; Glaucia Sayuri Arita; Franciele Abigail Vilugron Rodrigues-Vendramini; Admilton Gonçalves de Oliveira Junior; Maria Sueli Soares Felipe; Patrícia de Souza Bonfim de Mendonça; Terezinha Inez Estivalet Svidzinski; Erika Seki Kioshima
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

8.  Extraction and Optimization of Active Metabolites From Cluster Bean: An In Vitro Biological and Phytochemical Investigation.

Authors:  Saima Riaz; Iqbal Hussain; Muhammad Ibrahim; Muhmmad Ishtiaq; Qasim Ali; Muhammad Muazzam Ali; Muhammad Sajid Hamid Akash
Journal:  Dose Response       Date:  2022-05-07       Impact factor: 2.623

9.  Cell wall mannan of Candida krusei mediates dendritic cell apoptosis and orchestrates Th17 polarization via TLR-2/MyD88-dependent pathway.

Authors:  Thu Ngoc Yen Nguyen; Panuwat Padungros; Panachai Wongsrisupphakul; Noppadol Sa-Ard-Iam; Rangsini Mahanonda; Oranart Matangkasombut; Min-Kyung Choo; Patcharee Ritprajak
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.